- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07591038
PET/CT Imaging in Carriers of TTR Mutations (EPIC-TTR)
Iodine-124 Evuzamitide PET/CT Imaging in Carriers of TTR Mutations
The purpose of this study is to determine if TTR gene carriers have early signs of a type of heart disease called amyloidosis using a new radiotracer dye (iodine-124 evuzamitide, I-124E).
Participants will undergo a screening that includes a medical history review and completion of quality-of-life surveys. Once screening is complete, participants will undergo an imaging test called a positron emission tomography (PET) scan combined with computed tomography (PET/CT) to make images of the body. The new radiotracer dye (I-124E, a radioactive contrast) will be used during the PET/CT to make amyloidosis visible in the heart and body.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Amy Browning
- Numéro de téléphone: 214-645-8040
- E-mail: Amy.Browning@utsouthwestern.edu
Sauvegarde des contacts de l'étude
- Nom: Jerah Sanchez
- Numéro de téléphone: 214-645-7303
- E-mail: jerahmarie.sanchez@utsouthwestern.edu
Lieux d'étude
-
-
Texas
-
Dallas, Texas, États-Unis, 75248
- UT Southwestern Medical Center
-
Chercheur principal:
- Justin L Grodin, MD MPH
-
Sous-enquêteur:
- Lori Roth, PA-C
-
Contact:
- Jerah Sanchez
- Numéro de téléphone: 214-645-7303
- E-mail: jerahmarie.sanchez@utsouthwestern.edu
-
Sous-enquêteur:
- Vlad Zaha, MD PhD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
La description
A. Pathogenic TTR Allele Carriers without HF
Inclusion:
- men and women ages 30-80 who are pathogenic allele TTR carriers without history of HF (this will be assessed by study personnel and defined as : 1) No history of hospitalization within the previous 12 months for management of HF; 2) Without an elevated B-type natriuretic peptide level ≥100 pg/mL or NT-proBNP ≥360 pg/mL within the previous 12 months; or 3) a clinical diagnosis of HF from a treating clinician)
- have already completed the protocol for NCT05489549 at UT Southwestern only
Exclusion:
- a self-reported history or clinical history of HF
- other known causes of cardiomyopathy
- history of light-chain cardiac amyloidosis
- prior type 1 myocardial infarction
- cardiac transplantation
- liver transplantation
- body weight or habitus that exceeds the site-specific PET/CT parameters
- estimated glomerular filtration rate ≤30 mL/min/1.73 m2
- inability to safely undergo PET/CT
- participating in a clinical trial for ATTR treatments or taking a fibril deleting agent
- pregnancy or breastfeeding
- patients taking heparin or heparin derivatives for anticoagulation
- allergy to potassium iodide
- known uncorrected thyroid disorder
B. Subjects with symptomatic hATTR-CA (may be supplemented with other ATTR-CA genotypes including wild-type in the occasion of slow enrollment):
Inclusion:
- men and women ages 30-80 who have symptomatic V122I hATTR-CA as determined by a history of HF (this will be assessed by study personnel and defined as : 1) history of hospitalization within the previous 12 months for management of HF; 2) an elevated B-type natriuretic peptide level ≥100 pg/mL or NT-proBNP ≥360 pg/mL within the previous 12 months; or 3) a clinical diagnosis of HF from a treating clinician)
- hATTR-CA previously diagnosed histologically by amyloid staining and tissue typing with immunohistochemistry or mass spectrometry or by bone scintigraphy in without abnormal M-protein
- TTR gene sequencing confirming the TTR variant
- have already completed the protocol for NCT05489549 at UT Southwestern only
Exclusion:
- other known causes of cardiomyopathy
- history of light-chain cardiac amyloidosis
- cardiac transplantation
- liver transplantation
- history of type I myocardial infarction
- body weight or habitus that exceeds the site-specific PET/CT parameters
- estimated glomerular filtration rate ≤30 mL/min/1.73 m2
- inability to safely undergo PET/CT
- participating in a clinical trial for ATTR treatments or taking a fibril deleting agent
- patients taking heparin or heparin derivatives for anticoagulation
- pregnancy or breastfeeding
- allergy to potassium iodide
- known uncorrected thyroid disorder
C. Non-carrier race-matched controls:
Inclusion:
- men and women ages 30-80 who are non-carriers without history of HF (this will be assessed by study personnel and defined as: 1) No history of hospitalization within the previous 12 months for management of HF; 2) Without an elevated B-type natriuretic peptide level ≥100 pg/mL or NT-proBNP ≥360 pg/mL within the previous 12 months; or 3) No clinical diagnosis of HF from a treating clinician
- have previously enrolled in the Dallas Heart Study
Exclusion:
- a self-reported history or clinical history of HF
- other known causes of cardiomyopathy
- history of light-chain cardiac amyloidosis
- prior type 1 myocardial infarction
- cardiac transplantation
- liver transplantation
- body weight or habitus that exceeds the site-specific PET/CT parameters
- estimated glomerular filtration rate ≤30 mL/min/1.73 m2
- inability to safely undergo PET/CT
- participating in a clinical trial for ATTR treatments or taking a fibril deleting agent
- patients taking heparin or heparin derivatives for anticoagulation
- pregnancy or breastfeeding
- allergy to potassium iodide
- known uncorrected thyroid disorder
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Pathogenic TTR Allele Carriers without Heart Failure
|
I-124E is a novel amyloidophilic peptide radiotracer that binds via electrostatic interactions to electronegative glycosaminoglycans and amyloid protein fibrils - both are ubiquitous among amyloid deposits.
PET/CT I-124E has acceptable dosimetry estimates and is acceptable for whole-body PET/CT imaging.
Data from patients with amyloidosis has established that tracer uptake is present in locations of clinically anticipated amyloid deposits and in locations not clinically appreciated, but also consistent with the distribution of amyloid in the human body (e.g.
heart, kidney, spleen).
|
|
Subjects with Symptomatic ATTR-CA
|
I-124E is a novel amyloidophilic peptide radiotracer that binds via electrostatic interactions to electronegative glycosaminoglycans and amyloid protein fibrils - both are ubiquitous among amyloid deposits.
PET/CT I-124E has acceptable dosimetry estimates and is acceptable for whole-body PET/CT imaging.
Data from patients with amyloidosis has established that tracer uptake is present in locations of clinically anticipated amyloid deposits and in locations not clinically appreciated, but also consistent with the distribution of amyloid in the human body (e.g.
heart, kidney, spleen).
|
|
Non-carrier race-matched controls
|
I-124E is a novel amyloidophilic peptide radiotracer that binds via electrostatic interactions to electronegative glycosaminoglycans and amyloid protein fibrils - both are ubiquitous among amyloid deposits.
PET/CT I-124E has acceptable dosimetry estimates and is acceptable for whole-body PET/CT imaging.
Data from patients with amyloidosis has established that tracer uptake is present in locations of clinically anticipated amyloid deposits and in locations not clinically appreciated, but also consistent with the distribution of amyloid in the human body (e.g.
heart, kidney, spleen).
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
LV % Injected dose
Délai: PET/CT Scan Visit
|
Evidence of subclinical cardiac amyloid infiltration as measured by PET/CT quantification imaging with I-124E.
This will be defined as LV % injected dose (LV%ID = volume of interest [VOI] mean activity concentration in the LV X VOI volume / injected activity).
LV%ID is an ideal metric to assess cardiac amyloid burden because it is: 1) correlated with validated metrics assessing cardiac amyloid burden; 2) sensitive for detection of early disease (patchy vs. diffuse uptake); and 3) highly repeatable and standardizable to other metrics of radiotracer uptake.
LV%ID is adjusted for injected activity, but not for body weight, because the latter is unnecessary for a radiotracer accumulating in the heart and specific organs, not in the whole body.
|
PET/CT Scan Visit
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
LVFW SUVR, mean
Délai: PET/CT Scan Visit
|
PET/CT Scan Visit
|
|
LVFW wall SUVR, max
Délai: PET/CT Scan Visit
|
PET/CT Scan Visit
|
|
IVS SUVR, mean
Délai: PET/CT Scan Visit
|
PET/CT Scan Visit
|
|
IVS SUVR, max
Délai: PET/CT Scan Visit
|
PET/CT Scan Visit
|
|
RVFW SUVR, mean
Délai: PET/CT Scan Visit
|
PET/CT Scan Visit
|
|
RVFW SUVR, max
Délai: PET/CT Scan Visit
|
PET/CT Scan Visit
|
|
RV % Injected Dose (RV%ID)
Délai: PET/CT Scan Visit
|
PET/CT Scan Visit
|
|
LV Cardiac Amyloid Activity (CAA)
Délai: PET/CT Scan Visit
|
PET/CT Scan Visit
|
|
LV Target-to-Background Ratio (TBR)
Délai: PET/CT Scan Visit
|
PET/CT Scan Visit
|
|
RV Cardiac Amyloid Activity (CAA)
Délai: PET/CT Scan Visit
|
PET/CT Scan Visit
|
|
RV Target-to-Background Ratio (TBR)
Délai: PET/CT Scan Visit
|
PET/CT Scan Visit
|
|
Left Atrial Uptake
Délai: PET/CT Scan Visit
|
PET/CT Scan Visit
|
|
Right Atrial Uptake
Délai: PET/CT Scan Visit
|
PET/CT Scan Visit
|
|
Liver Uptake
Délai: PET/CT Scan Visit
|
PET/CT Scan Visit
|
|
Spleen Uptake
Délai: PET/CT Scan Visit
|
PET/CT Scan Visit
|
|
Kidney Uptake
Délai: PET/CT Scan Visit
|
PET/CT Scan Visit
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Justin L Grodin, MD MPH, University of Texas Southwestern Medical Center
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- STU-2026-0286
- R01HL172993 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .